The Latest Breaking News from Elanco Animal Health

In the latest quarter, 6 analysts provided ratings for Elanco Animal Health (NYSE:ELAN), showcasing a mix of bullish and bearish perspectives.

Elanco stock plummeted Thursday after the company announced a pair of delays and a surprise warning for its new eczema treatment for dogs.

According to Benzinga Pro, during Q1, Elanco Animal Health (NYSE:ELAN) earned $48.00 million, a 149.48% increase from the preceding quarter. Elanco Animal Health also posted a total of $1.23 billion in sales, a 10.06% increase since Q4.

Despite the company’s higher-than-industry average profitability and solid earnings growth prospects, the shares of Elanco Animal Health are trading way below their 52-week price high. So, is it wise to buy the dip in the stock? Read on to learn our view.

Elanco Animal Health (NYSE:ELAN) will host a conference call at 08:00 AM ET on May 9, 2022, to discuss Q1 2022 earnings results. How to Attend Elanco Animal Health (ELAN) Conference Call Follow this link to access the live webcast.

Given the unprecedented increase in pet ownership since the onset of the COVID-19 pandemic, rising consumer spending on pet food, medications, and other ancillary pet services has driven the pet care industry’s growth. Because high demand is expected to persist going forward, prominent pet stocks IDEXX Laboratories (IDXX) and Elanco…